BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
Apr 11, 2011
 |  BC Week In Review  |  Clinical News  |  Clinical Results

CTS-1027: Interim Phase II data

Interim data from 61 evaluable patients in an ongoing, single-arm, open-label, U.S. Phase II trial showed that twice-daily 15 mg CTS-1027 plus Pegasys peginterferon alfa-2a and Copegus ribavirin led to an early virologic response (EVR) rate, defined as a >=2 log10 IU/mL reduction...

Read the full 213 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >